Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

FDA Approves SAMSCA(TM) (tolvaptan), The First And Only Oral Vasopressin Antagonist To Treat Patients With Clinically Significant Hypervolemic
Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC) announced that the U.S. Food and Drug Administration (FDA) has approved SAMSCA(TM) (tolvaptan) as the only oral selective vasopressin antagonist for the treatment of patients with clinically significant hypervolemic and euvolemic hyponatremia (serum sodium less than 125 mEq/L, or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction) including patients with heart failure, cirrhosis, and the syndrome of inappropriate anti-diuretic hormone (SIADH). Patients requiring urgent treatment to raise serum sodium to prevent or to treat serious neurological deficits should not be treated with SAMSCA. Additionally, it has not been established that raising serum sodium with SAMSCA provides a symptomatic benefit to patients. SAMSCA, an oral vasopressin V2-receptor antagonist, will be commercialized in the United States by Otsuka America Pharmaceutical, Inc. (OAPI).
generic viagra online
IPS Examines Legislative Measures To Fight HIV/AIDS
Inter Press Service examines several civil society organizations" argument that legislative measures aimed at fighting HIV/AIDS, "hurt more" than they "help." There are 58 countries with laws in place to "prosecute HIV transmission" and 33 others where such legislation is being considered, according to the International Planned Parenthood Federation.
News of the day
New Pocket-Sized Breath Test Developed By TAU
A quick breath check in the palm of your hand can never give accurate results. Whether you"re about to lean in for a smooch or start a job interview, you"re better off asking a trusted friend if your breath is sweet. But what if a friend isn"t around when you need one?
Health Insurance

European Union Research Grant Awarded To University Of Haifa Research Team

The research team is headed by Prof. Kobi Rosenblum of the University of Haifa"s Department of Neurobiology and Ethology and has been awarded a grant of $815,000 A research team composed of 14 European groups, headed by Prof. Nils Brose of the Max Planck Institute for Experimental Medicine, has been awarded 11.9 million Euro, on behalf of the European Union, to study the role of synaptic proteins in neurological and psychiatric diseases. One of the research teams is headed by Prof. Kobi Rosenblum of the University of Haifa"s Department of Neurobiology and Ethology and has been awarded a grant of 600,000 Euro. The topic of the grant is "Synaptic protein networks in neurological and psychiatric disease." Many neurological diseases result from mis- or damaged expression of proteins in the links between the nerve cells - the synapses. The goal of the research is to cause deliberate damage to the function of various proteins in the synapses, so as to create disease models that result from abnormal functioning of proteins in the brain, such as autism and schizophrenia. The process is based on the existing knowledge of the function of different proteins and according to medical knowledge relating to people with different brain disorders such as autism and schizophrenia. Rachel Feldman University of Haifa


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009